Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

Heather Landau, Shahzad Raza, Aaron Rosenberg, Jeffrey Zonder, Raymond Comenzo, Vaishali Sanchorawala, Michaela Liedtke, Amandeep Godara, Michael Rosenzweig, Charlotte Hughes, Eugene Brailovski, Mehrdad Abedi, Sham Mailankody, Jae Park, David Marks, Sridevi Rajeeve, Jennifer Liu

Blood (2025) 146 (Supplement 1): 696.

https://doi.org/10.1182/blood-2025-696

Published: 2025

Journal Articles

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Blood (2025) 146 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2025-2369

Published: 2025

Journal Articles

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2025-1565

Published: 2025

Journal Articles

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study

Blood (2025) 146 (Supplement 1): 374.

https://doi.org/10.1182/blood-2025-374

Published: 2025

Journal Articles

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Blood (2024) 144 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2024-199287

Published: 2024

Journal Articles

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Blood (2024) 144 (Supplement 1): 4206.

https://doi.org/10.1182/blood-2024-200239

Published: 2024

Journal Articles

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Charles Craddock, David Marks, Victoria Potter, Wendy A Ingram, Rebecca Collings, Eleni Tholouli, Rachel Protheroe, Hugh Allen, Alex Ross, Dawn Farrar, Shamyla Siddique, Rebecca Bishop, Ronjon Chakraverty

Blood (2023) 142 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2023-188490

Published: 2023

Journal Articles

Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Christy Finke, BS, Abhishek A. Mangaonkar, MBBS, Christopher Pin, PhD, Kurt Berger, Tamas Ordog, MD, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Alexandre Gaspar Maia, PhD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134964

Published: 2020

Journal Articles

ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility

Moritz Binder, MDMPH, Sandeep Potluri, MA, MBBChir, MRCP, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Christy Finke, BS, Abhishek A. Mangaonkar, MBBS, Christopher Pin, PhD, Kurt Berger, Tamas Ordog, MD, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Alexandre Gaspar Maia, PhD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-134977

Published: 2020

Journal Articles

Epigenomic Determinants of Transcriptional Activity in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Alexandre Gaspar Maia, PhD, Ryan M. Carr, MD PhD, Christopher Pin, PhD, Kurt Berger, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 2987.

https://doi.org/10.1182/blood-2019-123191

Published: 2019

Journal Articles

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Ryan Carr, MD PhD, Nathalie Droin, PhD, Abhishek A Mangaonkar, MBBS, Giacomo Coltro, MD, Luciana L Almada, PhD, David Marks, PhD, Kurt Berger, Terra Lasho, PhD, Naseema Gangat, MBBS, Christopher Pin, PhD, Martin Fernandez-Zapico, MD, Eric Solary, MD PhD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4232.

https://doi.org/10.1182/blood-2019-122187

Published: 2019

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

Distal Enhancer Elements in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Alexandre Gaspar Maia, PhD, Ryan M. Carr, MD PhD, Terra Lasho, PhD, Thomas E. Witzig, MD, Christopher Pin, PhD, Kurt Berger, Bonnie Alver, PhD, Keith Robertson, PhD, David Marks, PhD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 2981.

https://doi.org/10.1182/blood-2019-124917

Published: 2019

Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2018-99-110552

Published: 2018

Journal Articles

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao, MD, Katherine Clesham, Jack Luke Bartram, MD, Phil Ancliff, Sara Ghorashian, FRCPath, PhD, David O'Connor, Vesna Pavasovic, Anupama Rao, MD, Sujith Samarasinghe, Carole Cairns, David Marks, David Taussig, PhD MRCP, FRCPath, Ajay Vora, MD

Blood (2018) 132 (Supplement 1): 5201.

https://doi.org/10.1182/blood-2018-99-117051

Published: 2018

Journal Articles

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

David Marks, Wendy Gidman, PhD MSc, BPharm, Heather M Wieffer, PhD, Lirong Zhang, MSc, Ze Cong, PhD MS, Shweta Shah

Blood (2018) 132 (Supplement 1): 5865.

https://doi.org/10.1182/blood-2018-99-118029

Published: 2018

Journal Articles

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

Dina Ahmed Said Aly Okasha, MBBS, MSc, Amy A Kirkwood, Krisztina Zuborne Alapi, MSc, Rachel J Mitchell, MSc, Pedro Santos e Sousa, MD PhD, Daniel Leongamornlert, PhD, Elli Papaemmanuil, PhD, David Marks, MD PhD, Ronjon Chakraverty, BMBS, PhD, Adele K Fielding, MBBS,PhDFRCP,FRCPath

Blood (2017) 130 (Supplement 1): 1317.

https://doi.org/10.1182/blood.V130.Suppl_1.1317.1317

Published: 2017

Journal Articles

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Matthias Stelljes, MD, Daniel J. DeAngelo, MD, Nicola Goekbuget, MD, Hagop M. Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Tao Wang, PhD, Hui Zhang, Fausto Loberiza, Erik Vandendries, MD PhD, David Marks

Blood (2017) 130 (Supplement 1): 886.

https://doi.org/10.1182/blood.V130.Suppl_1.886.886

Published: 2017

Journal Articles

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Blood (2016) 127 (20): 2427–2438.

https://doi.org/10.1182/blood-2015-11-679639

Published: 2016

Includes: Supplemental data

Journal Articles

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Dina Okasha, Amy A Kirkwood, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Emma Lawrie, Andrew McMillan, PhD, Tobias F. Menne, MD PhD FRCPath, Nick Morley, Clare Rowntree, Deborah Susan Richardson, MDFRCPath,FRCP,MA,MBBChir, Paul Smith, Adele K. Fielding, MB BS, PhD, David Marks, MD PhD

Blood (2015) 126 (23): 733.

https://doi.org/10.1182/blood.V126.23.733.733

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia

ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility

Epigenomic Determinants of Transcriptional Activity in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Distal Enhancer Elements in ASXL1 -Mutant Chronic Myelomonocytic Leukemia

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Clinicians' Perspectives on Cure in Adult Acute Lymphoblastic Leukemia (ALL) Patients with Minimal Residual Disease (MRD) - Findings from a UK Delphi Panel

Bone Marrow Infiltrating T-Cell Signatures Following Allo-HCT for Adult Acute Lymphoblastic Leukaemia Differentiate between Patients in Continuous CR and Those with Persistent Minimal Residual Disease or Relapse

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only